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ABSTRACT
INTRODUCTION: Tumor-infiltrating CD8+ T cells are associated with improved 
clinical outcomes in non-small cell lung cancer (NSCLC). Here we studied their 
prognostic effect in the context of the expression of HLA molecules that are key in 
tumor recognition (HLA-A, B and C) or suppression of immunity (HLA-E) as this is 
still unknown.
METHODS: Tumor tissue of 197 patients with resected pulmonary adenocarcinoma 
was analyzed for the presence of CD8+ T cells and the expression of β2-microglobulin, 
HLA-A, HLA-B/C and HLA-E. The relation of these parameters with overall survival 
(OS) was assessed.
RESULTS: Loss and low expression of HLA-A or HLA-B/C was found in 44% and 
75% of cases respectively. A high CD8+ tumor infiltration was strongly associated 
with clinical benefit only when the tumors retained good expression of HLA-A and 
HLA-B/C (p=0.004). In addition, more than 70% of the tumors were found to display a 
high expression of HLA-E. The expression of HLA-E by tumor cells was an independent 
negative prognostic factor for OS (p=0.031). Importantly, a dense stromal CD8+ T cell 
infiltration was strongly associated with improved OS only in HLA-E negative tumors 
(p=0.005) and its prognostic effect was completely abolished when tumors highly 
expressed HLA-E (p=0.989).
CONCLUSIONS: CD8+ T cell infiltration strongly contributes to a better prognosis 
in NSCLC when the tumor cells retain the expression of classical HLA class I and do 
not express HLA-E. Therefore, analysis of HLA-A, -B/C and HLA-E expression should 
be included as biomarkers to predict the response to immunotherapy.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is a leading 
cause of death globally [1–3]. The reported overall 5-year 
survival is 17% [2, 4], indicating the need for therapies that 
extend survival and provide a better quality of life. T-cell 
based immunotherapies hold great promise as a powerful 
new approach to treat NSCLC as treatment with antibodies 
interrupting immune checkpoint PD-1/PD-L1 has shown 
great clinical benefit in NSCLC [5–7]. The programmed 
death 1 (PD-1) receptor blocking antibody nivolumab 
was recently approved by the U.S. Food and Drug 
Administration to treat metastasized squamous NSCLC [8].
T-cell based immunotherapy of cancer is highly 
dependent on the presentation of tumor-specific antigens in 
the context of human leukocyte antigen (HLA) class I or 
class II molecules to tumor-infiltrating T cells (TILs) [9]. 
In NSCLC, the density of TILs, in particular the number of 
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stromal CD8+ T cells, have strong prognostic value [10–
15]. The expression of the classical HLA class I molecules 
A, B and C in NSCLC, however, frequently is down 
regulated [16, 17] and was found to affect overall survival 
(OS) [18]. Remarkably, studies on the interaction between 
CD8+ T cell infiltration and the expression of classical HLA 
class I are limited to one study showing that loss of HLA 
class I is associated with a sparser T-cell infiltrate [19].
The non-classical HLA class I molecules E, F and G 
can also be expressed by cancer cells. HLA-G expression 
was associated with limited lymphoid infiltration and 
poor prognosis in NSCLC [20], potentially via increased 
regulatory T-cell activity [21]. The expression of HLA-F, 
acting via the immune inhibitory receptors ILT-2 and 
ILT-4 [22], also had a negative impact on the prognosis 
of NSCLC patients [23]. HLA-E, which binds to the 
inhibitory CD94/NKG2A receptor expressed by activated 
NK cells and CD8 T cells, can directly suppress innate and 
adaptive immunity when expressed by cancer cells [24, 
25]. We have studied the expression of HLA-E in different 
cancers [26, 27] and found that the beneficial prognostic 
effect of infiltrating CTLs in ovarian cancer was thwarted 
by high expression of HLA-E [27]. However, the 
expression and prognostic effect of HLA-E in NSCLC has 
not been studied.
To investigate the prognostic value of CD8+ 
tumor infiltrating T cells in the context of HLA-A, B 
and C as well as HLA-E and its association with OS, 
we retrospectively studied a group of 197 patients 
with NSCLC. We exclusively focused on pulmonary 
adenocarcinoma not only because this is the main 
histological subtype in NSCLC [1, 28] but also because 
HLA loss has been reported to be less frequent than in 
squamous cell carcinoma, the other major subtype of 
NSCLC [16–19, 29] and therefore is expected to benefit 
the most from active T-cell-mediated immunotherapy. 
Our study revealed that the expression of HLA-E by 
tumor cells was an independent prognostic factor for 
OS. High expression of HLA-E neutralized the positive 
prognostic value of high stromal CD8+ T cell infiltration 
in NSCLC.
RESULTS
Stromal CD8 T-cell infiltration correlates best 
with overall survival
A cohort of 197 patients with pulmonary 
adenocarcinoma was evaluated. The grade of 
differentiation by the tumor was classified as either poor 
(50%), moderate (33%) or well differentiated (17%). In 
31% of cases, patients had advanced disease (stage III/IV) 
despite being classified as stage I/II based on pre-operative 
diagnostic modalities (Table 1). Mean age was 66 years 
(range 37- 90 years) and the number of males (n=99) and 
females (n=98) was evenly distributed.
The extent of CD8+ T-cell infiltration was studied 
by enumeration of intraepithelial and stromal CD8+ 
T cells in tumor sections. Examples of representative 
immunohistochemical stainings of CD8+ T cells are 
displayed in Figure 1. Overall intraepithelial CD8+ 
T-cell infiltration ranged from 7 to 1460 cells/ mm2 tumor 
(mean 194; median 150), stromal CD8+ T cells from 35 
to 1332 cells/ mm2 tumor (mean 348; median 320) and 
total CD8+ T cells from 32 to 1008 cells/ mm2 tumor 
(mean 271; median 246). There were no differences in 
total CD8+ T-cell tumor infiltration between males and 
females (chi square test, p=0.267). Patients were divided 
in two groups with low or high CD8+ T cell infiltration, 
based on the mean CD8+ T-cell count for all patients, 
and the association with OS was plotted. A relatively 
strong stromal CD8+ T-cell infiltration displayed the best 
association with a beneficial clinical outcome (log-rank 
test, p=0.068; Figure 2A–2C). The negative effect of low 
stromal CD8+ T-cell infiltration was magnified when the 
patients were divided on the basis of tertiles, with patients 
in the lower tertile defined as having low CD8+ stromal 
T cell infiltration and the other patients as having high 
stromal CD8+ T cell infiltration (p=0.046, Supplementary 
Figure S1), similar to what was reported before [10–14].
Interaction between classical HLA class I 
expression and CD8+ T cells
Assessment of the expression of classical HLA class 
I molecules was performed using antibodies against β2-M, 
HLA-A and HLA-B/C (Figure 1). β2-M was expressed in 
76% of cases, but HLA-A and HLA-B/C were expressed 
in only 56% and 25% of the cases, respectively (Table 1).
Subsequently, the association between tumor stage, 
HLA class I molecules and CD8+ T cell infiltration was 
assessed (Supplementary Table S1). High expression 
of HLA-A strongly correlated with high expression 
of HLA-B/C (p=0.0001). A clear correlation existed 
between the presence or absence of functional HLA class 
I expression and the total number of tumor-infiltrating 
CD8+ T cells. Tumors with downregulation of HLA-A 
(p=0.012) or HLA-B/C (p=0.018) displayed on average 
lower numbers of total tumor-infiltrating T cells 
(Supplementary Table S1 and Supplementary Figure S2).
When patients were grouped according to a low or 
high expression of HLA-A or HLA-B/C, Kaplan Meier 
curves did not reveal any direct impact of classical HLA 
class I expression on clinical outcome (Figure 2D and 
2E). However, an interaction analysis between classical 
HLA expression and total CD8+ T cell infiltration in 
tumor tissue revealed a clear beneficial effect of a dense 
CD8+ T cell infiltration in HLA-B/C positive tumors 
(HR 0.212, 95% CI 0.074-0.606, p=0.004) or HLA-A 
and HLA-B/C-positive tumors (HR 0.215, 95% CI 0.069-
0.673, p=0.008) with respect to OS (Table 2 and Figure 
3). This was not the case when CD8+ T-cell infiltration 
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was analyzed in the context of HLA-A expression only. 
These results indicate that the presence of high numbers 
of CD8+ T cells is correlated with a favorable prognosis 
when classical HLA class I expression by the primary 
tumor is retained.
HLA-E expression is a strong negative 
determinant for OS
In more than 70% of pulmonary adenocarcinoma 
cases a high expression of HLA-E was observed (Figure 
1F and Table 1). In 20.3% of these tumors displaying 
a functional HLA-E molecule, no expression of HLA-A 
and HLA-B/C was observed. The high expression of 
HLA-E was associated with worse OS (HR 0.632, 95% 
CI 0.406-0.984, p= 0.042; Table 2 and Figure 2F). Since 
both stromal CD8+ T-cell infiltration and the expression 
of HLA-E displayed the strongest effects on overall 
survival as a single determinant (Figure 2B and 2F, 
Supplementary Figure S1), a subsequent analysis was 
performed to study the interaction between these two 
factors. Clearly, a dense stromal CD8+ T cell infiltration 
showed a strong positive prognostic value in HLA-E 
negative tumors (HR 0.303, 95% CI 0.124-0.741, 
Table 1: Overview of stage, differentiation and immunohistochemical expression patterns in pulmonary 
adenocarcinoma
Surgical-pathological staging (number, %)
I 62 (31 %)
II 74 (38 %)
III 35 (18 %)
IV 26 (13 %)
Differentiation (number, %)
Poor 98 (50 %)
Moderate 66 (33 %)
Well 33 (17 %)
β2-M (number, %)
Low 47 (24 %)
High 150 (76 %)
HLA-A (number, %)
Low 87 (44 %)
High 110 (56 %)
HLA-B/C (number, %)
Low 148 (75 %)
High 49 (25 %)
HLA-E (number, %)
 Low 55 (28 %)
High 142 (72 %)
Total CD8+ (number, %)
Low 96 (59 %)
High 68 (41 %)
CD8+ in tumor (number, %)
Low 104 (64 %)
High 59 (36 %)
CD8+ in stroma (number, %)
Low 92 (56 %)
High 71 (44 %)
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p=0.009; Figure 4A and 4B). However, this beneficial 
effect of a dense stromal CD8+ T cell infiltration 
disappears in patients with high expression of HLA-E 
(HR 1.004, 95% CI 0.550-1.835, p=0.989; Figure 4C 
and 4D). In conclusion, the beneficial effect displayed 
by tumor-infiltrating stromal CD8+ T cells is impeded 
when HLA-E is highly expressed by tumors.
Figure 1: Staining of tumor infiltrating CD8+ T cells, β2-microglobulin, HLA-A, HLA-B/C and HLA-E in pulmonary 
adenocarcinoma. Formalin-fixed, paraffin embedded tumor specimens of 197 non-small cell lung cancer patients were cut in 4 µm 
sections and immunohistochemically stained for CD8, β2-microglobulin, classical HLA-A and HLA-B/C, as well as non-classical HLA-E. 
According to the Ruiter scoring system [46] both the intensity and percentage of cells stained were assessed and expression was categorized 
as low (score 1-4) and high (score 5-9). Examples are shown of high A. and low B. stromal and intraepithelial CD8+ T cell infiltration; 
tumor with high β2-microglobulin expression C. examples of HLA-A D. HLA-B/C E. and HLA-E F. staining. Original magnification x200.
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HLA-E expression is an independent 
determinant of OS in pulmonary 
adenocarcinoma
In order to assess the effect of each single variable 
on the relative risk of death, univariate and multivariate 
Cox proportional hazards analysis were performed to 
quantify survival differences (Table 2). Tumor stage and 
male gender have been reported before as negative risk 
factors for OS in pulmonary adenocarcinoma [30] and 
indeed in our cohort high stage tumors (stage I/II vs stage 
III/IV, HR 0.619, 95% CI 0.399-0.961, p=0.033) as well 
Figure 2: Association of CD8+ T cell infiltration and HLA expression with overall survival (OS). Patients were divided 
in two groups with low or high CD8+ T cell infiltration, based on the mean CD8+ T-cell count for all patients or on the basis of HLA 
expression. OS was defined as date of surgery until date of death due to any cause, or date of last follow-up with a maximum follow-up 
time of 5 years. Kaplan-Meier curves were used to estimate OS of the two groups whereas the log-rank test was used to compare the 
difference between the two curves. Survival curves are presented for A. patients with low (n=104) or high (n=59) intraepithelial CD8+ 
T cells (mean CD8+ cell count 194 cells/ mm2 tumor) ; B. low (n=92) or high (n=71) stromal CD8+ T cells (mean CD8+ cell count 
348 cells/ mm2 tumor) ; C. low (n=95) or high (n=68) total CD8+ T cells (mean CD8+ cell count 271 cells/ mm2 tumor). Furthermore, 
survival curves are presented for functional (i.e. positive staining for both HLA and β2-M) expression of D. HLA-A low (n=106) and 
high (n=91) ; E. HLA-B/C low (n=156) and high (n=41) ; F. HLA-E low (n=87) and high (n=110). A significant correlation (p=0.042) 
was observed between low HLA-E expression and improved survival (F).
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as male gender (HR 1.834, 95% CI 1.184-2.839, p=0.007) 
were associated with worse OS. In the univariate analysis, 
a low expression of non-classical HLA-E by tumor cells 
was associated with a strong reduced risk of death in 
this cohort (HR 0.632, 95% CI 0.406-0.984, p=0.042). 
Presence of high stromal CD8+ T cells correlated with 
improved OS and reached near-significance (HR 1.560, 
95% CI 0.962-2.530, p=0.072) and hence was included in 
the multivariate analysis together with tumor stage, gender 
and HLA-E expression.
Similar to the univariate analysis the positive effect 
of stromal CD8+ T cells on OS approached statistical 
significance (HR 1.613, 95% CI 0.993-2.620, p=0.054) 
in the multivariate analysis. In addition to tumor stage 
and gender, the increased expression of HLA-E was 
significantly associated with OS (HR 0.612, 95% CI 
0.392-0.956, p= 0.031) indicating that low HLA-E 
expression is an independent positive prognostic factor 
for OS in pulmonary adenocarcinoma.
DISCUSSION
The infiltration of NSCLC by CD8+ T cells is 
positively associated with a longer OS irrespective 
of tumor stage [10–15] and our study confirms this 
association of CD8+ T-cell infiltration with better OS. 
It is important to identify the most important factors 
governing a successful attack of NSCLC by CD8+ T 
cells as illustrated by the facts that a) more than 40% of 
NSCLC patients respond to checkpoint inhibitor therapy 
[5–7]; and b) especially those patients are likely to 
respond in whom the tumor has generated neo antigens 
for CD8+ T cells [31]. One of the key molecules in this 
process is the expression of HLA molecules required to 
present tumor-specific peptides to T cells. When measured 
with a pan-HLA class I antibody, the loss of HLA is 
observed in almost half of the patients with pulmonary 
adenocarcinoma [16–19, 32]. We used antibodies to 
distinct the expression of HLA-A and HLA-B/C in order 
Table 2: Univariate and multivariate cox proportional hazard analysis
Variable Univariate analysis Multivariate 
analysis
HR (95% CI) p value HR (95% CI) p value
Stage I/II vs III/IV 0.619 (0.399 - 0.961) 0.033 0.587 (0.377-
0.913)
0.018
Sex Male vs Female 1.834 (1.184 - 2.839) 0.007 1.785 (1.152-2.765) 0.009
Differentiation poor vs medium/well 1.423 (0.928 - 2.182) 0.106
β2-microglobulin low vs high 0.762 (0.442 - 1.314) 0.328
HLA-A low vs high 0.703 (0.462 - 1.084) 0.112
HLA-B/C low vs high 0.822 (0.498 - 1.358) 0.443
HLA-E low vs high 0.632 (0.406 - 0.984) 0.042 0.612 (0.392-
0.956)
0.031
Intraepithelial CD8 low vs high 0.682 (0.427 - 1.087) 0.108
Stromal CD8 low vs high 1.560 (0.962 - 2.530) 0.072 1.613 (0.993-2.620) 0.054
Total CD8 low vs high 1.130 (0.705 - 1.812) 0.659
HLA-E low high vs low stromal CD8 0.303 (0.124 - 0.741) 0.009
HLA-E high high vs low stromal CD8 1.004 (0.550 - 1.835) 0.989
Stromal CD8 high high vs low HLA-E 3.282 (1.308 - 8.232) 0.011
Stromal CD8 low high vs low HLA-E 1.032 (0.585 - 1.818) 0.914
HLA-B/C high high vs low total CD8 0.212 (0.074 - 0.606) 0.004
HLA-A and B/C high high vs low total CD8 0.215 (0.069 - 0.673) 0.008
Significant differences (p<0.05) are indicated in bold.
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Figure 3. Effect of classical HLA class I expression and CD8+ T cell infiltration on overall survival (OS). Patients were 
divided in two groups with low or high CD8+ T cell infiltration, based on the mean CD8+ T-cell count for all patients and on 
the expression of classical HLA class I. Kaplan-Meier curves were constructed to estimate OS of the two groups whereas the 
log-rank test was used to compare the difference between the two curves. A, B. Comparison of OS between patients with low 
or high total CD8+ T cell infiltration in the context of low (A; n=63 vs 30, respectively) or high (B; n=32 vs 38, respectively) 
HLA-A expression. C, D. Comparison of OS between patients with low (n=83) or high (n=47) CD8+ T cell infiltration of 
whom the tumors displayed low HLA-B/C expression (C). Comparison of OS between patients with HLA-B/C positive tumors 
and high (n=21) or low (n=12) total CD8+ T cell infiltration (D). E, F. Comparison of OS between patients with low (n=62) 
or high (n=27) CD8+ T cell infiltration in tumors with low expression of both HLA-A and HLA-B/C (E). Comparison of OS 
between patients with low (n=11) or high (n=18) total CD8+ T cell infiltration in the context of tumors with high expression 
of both HLA-A and HLA-B/C. (F)
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to chart the HLA loss in more detail (Table 1). We found 
that HLA-A was decreased in about 40% of the patients 
while the decrease in HLA-B/C expression was even as 
high as 75% which is in line with only one other study 
that reports specifically on loss of HLA-B/C in NSCLC 
[33]. In addition, interaction analyses of HLA expression 
and CD8+ T-cell infiltration led to the novel observation 
that the prognostic effect of a dense CD8+ T-cell tumor 
infiltration is only retained when tumors display a high 
expression of classical HLA class I, in particular HLA-
B/C (Figure 3).
Other key molecules governing a successful attack 
of T cells in NSCLC are the so-called checkpoints [34]. 
The non-classical HLA-E molecule is the ligand for the 
inhibition receptor CD94/NKG2A and represents an 
important immunologic checkpoint [24, 25]. This study is 
the first to show that a high expression of the non-classical 
HLA-E molecule affects overall survival in NSCLC. Both 
univariate and multivariate analysis revealed high HLA-E 
expression by tumor cells as an independent predictor of 
poor prognosis (Table 2 and Figure 2). The expression 
of HLA-E can inhibit the function of T lymphocytes and 
natural killer (NK) cells when it engages with CD94/
NKG2A [24, 25, 35], as well as activate these cells when 
HLA-E engages with CD94/NKG2C [36]. A few studies in 
breast cancer and cervical adenocarcinoma have reported 
survival benefit for HLA-E expressing tumors [37, 38] 
while others, similar to us, reported a negative effect 
of HLA-E on OS in ovarian cancer, colorectal cancer 
and gastric cancer [27, 39–41]. Potentially, the type of 
receptor for HLA-E expressed by CD8 T cells is at the 
basis of this difference. In ovarian cancer and colorectal 
cancer the T cells were shown to express the inhibitory 
receptor CD94/NKG2A [27, 39]. In line with previous 
studies in NSCLC, a dense stromal CD8+ T-cell tumor-
infiltrate was associated with longer OS (Figure 2 and 
Figure 4: Prognostic benefit in HLA-E negative tumors with high CD8+ T cell infiltration. Patients were divided in two 
groups with low or high stromal CD8+ T cell infiltration, based on the mean CD8+ T-cell count for all patients and on the expression 
of HLA-E. Kaplan-Meier curves were constructed to estimate OS of the two groups whereas the log-rank test was used to compare the 
difference between the two curves. A. The effect of CD8+ T cell infiltration in patients with low HLA-E expression (n=77), showing that 
a high stromal CD8+ T cell infiltration was strongly associated with a better OS. B. The effect of a high stromal CD8+ T cell infiltrate was 
neutralized in tumors with high HLA-E expression (n=86). C, D. Conversely, in patients with high stromal CD8+ T cell influx (n=71), 
a high HLA-E expression is associated with a worse OS (C). In patients with low presence of stromal CD8+ T cells (n=92), HLA-E 
expression had no effect on OS (D).
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Supplementary Figure 1) [10–15]. In our study, a high 
expression of HLA-E by tumor cells clearly had a negative 
effect on CD8+ T cells. The positive prognostic effect of 
stromal CD8+ T cells on OS was only apparent in patients 
with low expression of HLA-E on their tumor cells. A 
high tumor expression of HLA-E completely abolished the 
prognostic effect of CD8+ T-cell infiltrate (Table 2 and 
Figure 4).
Our study on the interaction between tumor 
expressed HLA and CD8+ T-cell infiltration in relation 
to survival raises two important issues. Currently, 
CD8+ T-cell infiltration and expression of PD-L1 are 
being considered as biomarkers to select the population 
of NSCLC patients that are most likely to respond to 
checkpoint antibody therapy [42]. Based on our data 
showing that the prognostic effect of CD8+ T cells is 
most pronounced in those tumors still expressing HLA-
B/C, one could consider including the analysis of classical 
HLA class I expression in this selection procedure. The 
second issue concerns the improvement of current PD-1/
PD-L1 therapy or alternative checkpoint treatment 
strategies in NSCLC. Our results showed that about 70% 
of the pulmonary adenocarcinomas displayed a high 
expression of HLA-E (Table 1). In view of its effect on 
both T cells and NK cells, blocking HLA-E and/or its 
CD94-NKG2A inhibitory receptor may form a valuable 
target for the immunotherapy of NSCLC. Treatment 
with anti-NKG2A monoclonocal antibody was shown to 
overcome HLA-E mediated suppression of anti-tumor 
cellular cytotoxicity in vitro [43, 44] and this has resulted 
in a currently ongoing phase I/II trial in which patients 
with advanced head and neck cancer are treated with an 
anti-NKG2A monoclonocal antibody (ClinicalTrials.gov, 
Identifier: NCT02331875). Potentially, a combination of 
antibodies to these two different checkpoints may even 
have a synergistic effect.
In conclusion, our results confirm the pivotal 
protective role of tumor infiltrating CD8+ T cells 
in NSCLC and in addition show that their effect is 
particularly apparent when the tumor cells retain the 
expression of classical HLA class I and do not express 
the non-classical molecule HLA-E. These results warrant 
the inclusion of HLA-A, -B/C and HLA-E as biomarkers 
to predict the response to immunotherapy and the use of 
HLA-E or NKG2A blocking antibodies for the treatment 
of NSCLC.
MATERIALS AND METHODS
Study population
We retrospectively identified 197 patients diagnosed 
with non-small cell lung cancer (NSCLC), subtype 
adenocarcinoma, in the Leiden University Medical Center 
(LUMC) between 2000 and 2013. All patients underwent 
preoperative staging and were classified as stage I/II 
NSCLC and subsequently underwent surgical resection of 
the primary tumor with systematic lymph node dissection. 
After surgical removal of the tumor and its draining lymph 
nodes, patients were considered disease free. Tumor tissue, 
clinical data and follow-up data were collected from all 
patients. Staging of NSCLC was determined according to 
the TNM (Tumor, Node, Metastasis) classification using 
the updated guidelines of the International Association 
for the Study of Lung Cancer (IASLC) [45]. The use of 
archival tumor blocks was in accordance with guidelines 
from the Dutch Federation of Medical Research 
Association. Since this retrospective study does not fall 
under the scope of the Medical Research Involving Human 
Subjects Act (WMO), it was not subject to a prior review 
by a Medical Ethical Committee and written informed 
consent was not obtained. However, patient data were 
anonymized.
Antibodies
Mouse monoclonal antibodies HCA-2 (anti HLA-A, 
1:1000) and HC-10 (anti HLA B/C, 1:500) were used to 
detect expression of the free heavy chain of the HLA 
class I molecule. Rabbit anti-human β2-microglobulin 
(anti-β2M; clone A-072, DAKO, 1:2000) and mouse anti-
human HLA-E (clone MEM-E/02; Serotec, Germany 
[1:200]) antibodies were used in order to detect the light 
chain and non-classical HLA-E heavy chain respectively. 
Mouse monoclonal CD8 antibody (clone IA5, Leica 
Biosystems, Germany [1:500]) was used for the detection 
of the CD8+ T-cells.
Immunochemistry
Formalin-fixed, paraffin embedded tumor blocks 
were cut in 4 µm sections using a microtome and 
deparaffinized in xylene. The endogenous peroxidase 
activity was blocked for 20 minutes using 0.3% 
hydrogen peroxide/methanol. The samples were 
subsequently rehydrated in 70% and 50% ethanol 
and antigen retrieval was performed by heating the 
samples to 97 °C for 10 minutes in citrate buffer 
(either pH 9.0 or pH 6.0, DAKO, Glostrup, Denmark). 
Antibodies were diluted in phosphate buffered saline 
(PBS, Fresenius Kabi Bad Homburg, Germany) 
with 1% bovine serum albumin (BSA) and incubated 
overnight at room temperature. The slides were stained 
immunohistochemically with horseradish peroxidase 
(HRP)-conjugated anti-mouse IgG (DAKO envision) 
for 30 minutes at room temperature. NovaRed (Vector, 
Burlingame, USA) was applied as a chromagen 
followed by counterstaining with Mayer’s hematoxylin 
(Klinipath). All washing steps were done with PBS. 
All slides were mounted with Pertex mounting medium 
(HistoLab, Sweden).
The microscopic evaluation and analysis of the 
HCA2, HC10, β2M and HLA-E staining was performed 
by two independent observers without prior knowledge 
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of clinical or histopathological parameters (observer one 
100% of the cohort, observer two 20% of the cohort). 
The inter-observer agreement was assessed by calculating 
Cohen's kappa coefficient resulting in a coefficient of 
>0.70 for all stainings which indicates a substantial inter-
observer agreement.
The grade of tumor differentiation was determined 
and classified as either poorly differentiated, moderately 
differentiated or well differentiated based on the 
immunohistochemically stained slides. Expression 
patterns of the previously mentioned antibodies were 
assessed according to the scoring system proposed by 
the Ruiter et al [46]. Using this method the entire slide is 
screened and the percentage of positive tumor cells was 
classified as: absent 0%, sporadic 1-5%, local 6-25%, 
occasional 25-50%, majority 51-75% and large majority 
76-100% (1-6). Furthermore, this score includes intensity 
of the staining which is classified as negative, low, 
medium and high (0-3). The intensity was noted for all 
antibodies with the exception of CD8 since high intensity 
was always observed. The final score was based on both 
intensity and percentage and was categorized as 1-4 (low 
expression) and 5-9 (high expression).
Quantification of infiltrating CD8+ T-cells
CD8+ T-cell infiltration was assessed by screening 
five randomly captured high resolution (200X) images 
of each slide. The area of the tumor nests and stromal 
areas were marked and calculated using NIH-ImageJ 
software (v1.48). CD8+ T cells were counted by area 
and represented as the number of cells per mm2 of tumor 
area with a distinction between intraepithelial and stromal 
CD8+ T cells. The mean number of intraepithelial, stromal 
and total number of tumor-infiltrating CD8+ T cells were 
calculated and patients were dichotomized for high or low 
CD8+ T cell infiltration based on the mean CD8+ T cell 
infiltration for all patients.
Statistical analysis
Nonparametric Mann–Whitney U test was used to 
compare continuous variables between patient groups and 
group comparisons of categorical data were performed by 
two-tailed χ2 test. Overall survival (OS) was defined as 
date of surgery until date of death due to any cause, or date 
of last follow-up with a maximum follow-up time of 5 
years. When assessing survival based on HLA expression, 
low and high expression of HLA indicates the presence 
of a functional HLA molecule, i.e high expression of 
both β2M and the HLA heavy chain of HLA-A, HLA-
B/C and HLA-E respectively. Survival was estimated 
by using Kaplan—Meier methodology and the log-rank 
test was used to compare the two curves. Univariate Cox 
proportional hazards model was used to study the effect 
of single determinants on OS. Multivariate Cox regression 
analysis was performed with variables that reached 
statistical significance in univariate analysis. Stepwise 
regression was employed to estimate the final model. 
Two-sided P values of <0.05 were considered statistically 
significant. Bonferroni correction was applied for multiple 
testing. Statistical software package SPSS 20.0 (SPSS, 
Chicago, IL) was used for data analysis. GraphPad Prism 
6.02 (Graphpad Software, LA Jolla, CA) was used to 
estimate survival curves.
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